Phase 3 N=249 Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor
Adult Kidney Wilms Tumor · Beckwith-Wiedemann Syndrome · Childhood Kidney Wilms Tumor
Primary: Event-Free Survival (EFS) — 0.82 Probability
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=380 Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor
Stage III Kidney Wilms Tumor · Stage IV Kidney Wilms Tumor
Primary: Event Free Survival Probability — 0.79 Probability
Phase 3 N=808 Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor
Stage I Kidney Wilms Tumor · Stage II Kidney Wilms Tumor · Stage III Kidney Wilms Tumor
Primary: Event Free Survival Probability — 0.88; 0.87; 0.88 Probability
Phase 2 N=10 Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood
Leukemia, Acute Myelogenous (AML) · Leukemia, Acute Lymphocytic (ALL) · Leukemia, Chronic Myelogenous (CML)
Primary: Toxicity — 5 participants
Phase 2 N=62 Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma
Pleuropulmonary Blastoma · Recurrent Malignant Peripheral Nerve Sheath Tumor · Recurrent Neuroblastoma
Primary: Objective Response by Response Evaluation Criteria in Solid Tumors Version 1.1 — 0.00; 6.25; 0.00; 0.00 Percent of participants
Phase 2 N=20 Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
Childhood Hepatocellular Carcinoma · Papillary Thyroid Cancer · Previously Treated Childhood Rhabdomyosarcoma
Primary: Objective Response by RECIST Criteria v 1.1 — 10; 10; 0; 0 participants
Phase 2 N=291 Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors
Childhood Renal Cell Carcinoma · Clear Cell Renal Cell Carcinoma · Clear Cell Sarcoma of the Kidney
Primary: Event-Free Survival of Patients With Diffuse Anaplastic Wilms' Tumor (DAWT) — 76.1; 25.0; 87.5 Percentage of 4-year OS — p=.0199
N/A N=16 Pilot Trial of a WT-1 Analog Peptide Vaccine in Patients With Myeloid Neoplasms
Leukemia
Primary: Number of Participants With Adverse Events (AEs) — 15 participants
Phase 2 N=9 17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease
Hippel-Lindau Disease · Kidney Cancer
Primary: Number of Participants With a Renal Tumor Response — 0 participants
Phase 2 N=4 Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy
Myelodysplastic Syndrome · Acute Myeloid Leukemia (AML) · Chronic Myeloid Leukemia (CML)
Primary: Cellular Immune Response — 4 participants
Phase 2 N=41 Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy
Malignant Pleural Mesothelioma
Primary: 1-year Progression-free Survival — 44; 33 percentage of participants
Phase 1 N=62 Clinical Study of WT2725 in Patients With Advanced Malignancies
Cancer
Primary: Occurrence of Dose-limiting Toxicities and Adverse Events — 0; 0; 0; 0 number of occurances
Phase 2 N=19 Study Evaluating Biomarkers In Relapsed/Refractory Pediatric Solid Tumors
Adenocarcinoma · Neoplasms
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs): Part 1 — 4; 5; 3; 7 participants
Phase 2 N=36 RAPAMYCIN FOR KIDNEY ANGIOMYOLIPOMAS
Nonmalignant Neoplasm · Tuberous Sclerosis · Lymphangioleimyomatosis
Primary: Objective Response Rate — 44.4 percentage of participants
Phase 2 N=10 Busulfan, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk Ewing's Tumors
Sarcoma
Primary: Overall Objective Response — 4; 1 participants
Phase 2 N=13 Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer
Renal Cell Carcinoma · Graft-Versus-Host Disease · Engraftment Syndrome
Primary: Clinical Regression of Metastatic Renal Cell Carcinoma (Partial Response (PR)) or Complete Remission of Tumor (Complete Response (CR)) — 0; 0; 8; 1 participants
Phase 1 N=5 TIL Therapy for Metastatic Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma
Primary: Number of Patients in Which the Treatment Was Tolerable — 5 Participants
Phase 3 N=78 Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor
Stage I Adrenal Cortical Carcinoma AJCC v7 · Stage II Adrenal Cortical Carcinoma AJCC v7 · Stage III Adrenal Cortical Carcinoma AJCC v7
Primary: Five Year Event-free Survival (EFS) — 0.86; 0.53; 0.51 Estimated probability five year EFS — p=0.44
Phase 2 N=9 Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors
GIST
Primary: Number of Participants With a Clinical Activity-radiographic Response — 0; 0; 0; 0 Participants
Phase 2 N=19 Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer
Kidney Cancer
Primary: Progression-free Survival at 3 Months — 2.9 months
Phase 3 N=302 Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors
Childhood Embryonal Tumor · Childhood Extracranial Germ Cell Tumor · Childhood Extragonadal Germ Cell Tumor
Primary: Event-Free Survival (EFS) — 87.0 Percent probability
Phase 2 N=10 Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney Cancer
Clear Cell Renal Cell Carcinoma · Recurrent Renal Cell Cancer · Stage IV Renal Cell Cancer
Primary: Overall Efficacy, Taking Into Account Both Objective Response and Meaningful Reductions in Tumor Burden That do Not Meet the RECIST Criteria for PR or CR (e.g., 5-30%…
Phase 3 N=413 Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor
Brain and Central Nervous System Tumors
Primary: Progression-Free Survival (PFS) in ERBB2-Negative Tumors Compared to ERBB2-Positive Tumors — 79.2; 83.3; 69.6; 86.7 probability of PFS at 2 years — p=0.8001
Phase 3 N=70 Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System
Childhood Atypical Teratoid/Rhabdoid Tumor
Primary: Event-free Survival — 0.3401; 0.4500 Estimated probability
N/A N=31 Radiosurgery in Treating Patients With Kidney Tumors
Kidney Cancer
Primary: Maximum Tolerated Dose of Radiosurgery — 48; 60 Gy
Phase 2 N=102 BMS 247550 to Treat Kidney Cancer
Renal Cell Carcinoma
Primary: Response Rate — 1; 9.4; 12.6; 76.8 Percentage of participants
Phase 2 N=22 Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen
Advanced Malignancies · Advanced Cancer
Primary: Number of Participants With Treatment Emergent Adverse Events and Serious Adverse Events: Monotherapy — 3; 7; 2; 0 Participants
Phase 2 N=64 Therapy for Children With Advanced Stage Neuroblastoma
Neuroblastoma
Primary: Overall Response Rate [Complete Response + Very Good Partial Response + Partial Response (CR + VGPR + PR)] — 42 Participants
Phase 2 N=30 Everolimus for Cancer With TSC1 or TSC2 Mutation
TSC1 · TSC2 · Tuberous Sclerosis Complex
Primary: Objective Response Rate — 2 Participants
Phase 2 N=9 A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis
Desmoid Tumor
Primary: Immunohistochemical Immunoreactive Score Results After 4 Weeks of Sirolimus Compared to Control Specimens — 5.22; 7.44; 4.47; 9.39 score on a scale — p=0.63